|
**Overview**: Cytomegalovirus Antibodies Panel**Introduction**: The Cytomegalovirus Antibodies Panel is a diagnostic tool designed to screen for CMV infection using serum samples. In India, CMV seroprevalence is high (~80-90 percent in adults), with primary infection or reactivation causing significant morbidity in immunocompromised (HIV, transplant), pregnant women (congenital CMV), and neonates. IgM indicates recent/primary infection; IgG indicates past exposure. High burden from underdiagnosis in rural/low-SES pregnant women and transplant patients, limited serology access, delayed antiviral therapy leading to congenital defects or graft loss. Per microbiology practices aligned with ICMR and Indian Society of Infectious Diseases guidelines, the test employs immunoassay for IgG/IgM over 1-2 days with high sensitivity/specificity, valuable for screening in high-risk groups. This diagnostic falls under viral screening and targets pregnant women, transplant recipients, or immunocompromised patients, addressing accurate detection to guide monitoring or ganciclovir. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing congenital/transplant complications. Its serum-based approach ensures reliable detection.**Other Names**: CMV Ab Pnl.**FDA Status**: FDA approved, CLIA certified for immunology/microbiology, compliant with 2025 standards.**Historical Milestone**: CMV serology standard; in India, key in antenatal and transplant protocols.**Purpose**: The test screens for 2 parameters including CMV IgG and IgM to guide infection assessment, detect recent/past exposure, inform management.**Test Parameters**: 1. CMV IgG, 2. CMV IgM.**Pretest Condition**: No fasting required; patients should report fever, pregnancy, transplant status.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on pregnancy status, transplant, immunosuppression, symptoms.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated CMV including congenital defects, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or cross-reactivity can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive IgM indicates recent infection, IgG past exposure; necessitating specialist input. Negative may require follow-up in high-risk.**Specialist Consultation**: Infectious disease specialists or obstetricians should be consulted for management.**Additional Supporting Tests**: CMV PCR, avidity for confirmation.**Test Limitations**: IgM may persist; comprehensive approach required.**References**: Indian Journal of Medical Microbiology 2024, CMV Studies India 2023. |
